Koyfin Home > Directory > Health Care > Bristol-Myers Squibb Company > EBITDA

Bristol-Myers Squibb Company EBITDA Chart (BMY)

Bristol-Myers Squibb Company annual/quarterly EBITDA from 2010 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Bristol-Myers Squibb Company EBITDA for the quarter ending June 06, 2020 was $4,610m a 57.40% increase of 2,646m year over year
  • Bristol-Myers Squibb Company EBITDA for the last 12 months ending June 06, 2020 was $14,004m a 44.38% increase of 6,215m year over year
  • Bristol-Myers Squibb Company Annual EBITDA for 2019 was $8,740m a 19.85% increase of 1,735m from 2018
  • Bristol-Myers Squibb Company Annual EBITDA for 2018 was $7,005m a 34.86% increase of 2,442m from 2017
  • Bristol-Myers Squibb Company Annual EBITDA for 2017 was $4,563m a -25.12% decrease of -1,146m from 2016
Other Income Statement Metrics:
  • Bristol-Myers Squibb Company Net Income for the quarter ending December 12, 2018 was $1,192m a -24.66% decrease of -294m year over year
  • Bristol-Myers Squibb Company Total Revenue for the quarter ending December 12, 2018 was $5,973m a 13.06% increase of 780m year over year
View Chart On Koyfin

Quarterly BMY EBITDA Data

06/2020$4,610m
03/2020$4,782m
12/2019$2,603m
09/2019$1,964m
06/2019$2,229m
03/2019$1,942m
12/2018$1,654m
09/2018$1,879m
06/2018$1,819m
03/2018$1,653m

Annual BMY EBITDA Data

2019$8,740m
2018$7,005m
2017$4,563m
2016$5,709m
2015$4,435m
2014$4,146m
2013$4,180m
2012$5,289m
2011$7,787m
2010$7,012m